Altimmune, Inc. (ALT) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Altamune First Quarter 2025 Financial Results Conference Call. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Advisor to Altamune. Lee, you may begin. Thanks, Gigi, and good morning, everyone. Once again, thank you all for joining us for Altamune's first quarter 2025 Financial Results and Business Update conference call. On today's call, you'll hear from Dr. Vipengar, our Chief Executive Officer, Dr. Scott Harris, our Chief Medical Officer, and Greg Weaver, our Chief Financial Officer. Dr. Scott Roberts, our chief scientific officer, and Ray George, our chief business officer, are with us for the Q&A session. Our first quarter 2025 results and corporate update press release was issued earlier this morning and can be found on the investor relations section of the Altimmune website. Before we begin, I'd like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altamune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a full review of the risk factors that could affect the company's future results and operations, we refer you to the c...